Polyglutamated Antifolates for Selective Cancer Cell Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antifolate therapies for hyperproliferative diseases like cancer face challenges in delivering cytotoxic agents selectively to cancer cells while minimizing toxicity to normal healthy cells.
Innovation Solution
The development of novel alpha and D-gamma polyglutamated antifolate compositions, including liposomal formulations, that preferentially deliver polyglutamated antifolates to cancer cells, either through untargeted or targeted liposomes with specific affinity for folate receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If conventional antifolate therapies are used, then cytotoxic effect on cancer cells is achieved, but toxicity to normal healthy cells increases
Solution Approach 1:
The antifolate drug is segmented into different glutamated forms (monoglutamate, polyglutamate) with distinct properties. The monoglutamate form serves as a prodrug that is selectively converted to the active polyglutamate form inside cancer cells, while remaining relatively inert in normal cells. This segmentation allows differential activation and reduces off-target toxicity.
Solution Approach 2:
The enzyme FPGS (folylpolyglutamate synthetase) acts as an intermediary that selectively converts monoglutamate antifolates to polyglutamated forms. This enzyme is overexpressed in cancer cells compared to normal cells, creating a metabolic intermediary that enables selective drug activation in the target tissue and reduces systemic toxicity.
2Object-affected harmful factors
If polyglutamated antifolates are delivered directly, then cytotoxicity to cancer cells is enhanced, but cellular uptake is reduced
Solution Approach 1:
The antifolate is administered in the monoglutamate form, which serves as a preliminary inactive or low-activity state that is easily transported into cells. Once inside the cancer cell, the enzyme FPGS performs the preliminary action of converting it to the highly cytotoxic polyglutamate form. This preliminary action approach allows easy cellular uptake followed by selective activation.
Solution Approach 2:
The chemical structure of the antifolate is changed by varying the degree of glutamation (monoglutamate vs. polyglutamate). The monoglutamate form has parameters optimized for cellular uptake (smaller size, neutral charge), while the polyglutamate form has parameters optimized for cytotoxicity (larger size, negative charge, high enzyme affinity). The system dynamically changes between these parameter states through enzymatic conversion.
3Productivity
If untargeted liposomes are used, then delivery to cancer cells is improved, but specificity is reduced
Solution Approach 1:
The liposomal formulation utilizes the cancer cell's own overexpressed FPGS enzyme to selectively activate the drug after internalization. The system is self-service in that it leverages the metabolic characteristics of the target cells themselves to achieve selective activation, rather than requiring external targeting moieties. This self-service mechanism improves delivery efficiency while maintaining a degree of specificity through the enzyme's selective overexpression in cancer cells.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the efficacy of antifolate therapy by increasing the cytotoxicity of the antifolate payload and reducing toxicity to normal cells, thereby improving treatment outcomes for hyperproliferative diseases.
Implementation Method 1
delivery vehicles such as liposomes filled with the alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolates
Implementation Method 2
it allows selective intracellular retention of these relatively large anionic molecules
Implementation Method 3
the enzyme folylpolyglutamyl synthetase (FPGS), which may add up to 6 glutamyl groups in a L-gamma peptide linkage to the folate substrate
Implementation Method 4
Inhibition of the above enzymes suppresses de novo nucleotide biosynthesis, resulting in an imbalance of purine and pyrimidine precursors
Data Source
AI summary
The disclosure relates generally to polyglutamated antifolates, formulations containing liposomes filled with alpha or D-gamma polyglutamated antifolates, methods of making the polyglutamated antifolates and liposome containing formulations, and methods of using polyglutamated antifolates and liposome containing formulations to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).